Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reguera

Showing results (841-850 of 896) with videos related to

Pageof 90
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 7, 2019
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registryA Viúdez, A Carmona-Bayonas, J Gallego, et al.
Frontiers in Immunology|May 1, 2023
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignanciesClara Beatriz García-Calderón, Belén Sierro-Martínez, Estefanía García-Guerrero, et al.
Transplantation and Cellular Therapy|April 9, 2023
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell TherapyNicolas Gazeau, Emily C Liang, Qian Vicky Wu, et al.
Infection|September 26, 2020
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paperIbai Los-Arcos, Gloria Iacoboni, Manuela Aguilar-Guisado, et al.
Frontiers in Immunology|August 1, 2022
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish GroupsMariana Bastos-Oreiro, Antonio Gutierrez, Juan Luís Reguera, et al.
Frontiers in Immunology|November 3, 2025
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002hDaniel Munárriz, Luis Gerardo Rodríguez-Lobato, Lucía López-Corral, et al.
International Journal of Antimicrobial Agents|September 5, 2024
Early antibiotic de-escalation in patients with severe infections due to bloodstream infection by enterobacterales: A post hoc analysis of a prospective multicentre cohortFrancesc Escrihuela-Vidal, Zaira R Palacios-Baena, Josune Goikoetxea Agirre, et al.
Transplantation and Cellular Therapy|July 28, 2024
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMORebeca Bailén, Gloria Iacoboni, Javier Delgado, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatmentsAlfonso Cortés, José L Casado, Federico Longo, et al.
Journal of Clinical Medicine|August 16, 2020
Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter StudyAlba Herrero-Morant, Carmen Álvarez-Reguera, José L Martín-Varillas, et al.
Pageof 90

Showing results (841-850 of 896) with videos related to

Sort By:
Pageof 90
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 7, 2019
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registryA Viúdez, A Carmona-Bayonas, J Gallego, et al.
Frontiers in Immunology|May 1, 2023
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignanciesClara Beatriz García-Calderón, Belén Sierro-Martínez, Estefanía García-Guerrero, et al.
Transplantation and Cellular Therapy|April 9, 2023
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell TherapyNicolas Gazeau, Emily C Liang, Qian Vicky Wu, et al.
Infection|September 26, 2020
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paperIbai Los-Arcos, Gloria Iacoboni, Manuela Aguilar-Guisado, et al.
Frontiers in Immunology|August 1, 2022
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish GroupsMariana Bastos-Oreiro, Antonio Gutierrez, Juan Luís Reguera, et al.
Frontiers in Immunology|November 3, 2025
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002hDaniel Munárriz, Luis Gerardo Rodríguez-Lobato, Lucía López-Corral, et al.
International Journal of Antimicrobial Agents|September 5, 2024
Early antibiotic de-escalation in patients with severe infections due to bloodstream infection by enterobacterales: A post hoc analysis of a prospective multicentre cohortFrancesc Escrihuela-Vidal, Zaira R Palacios-Baena, Josune Goikoetxea Agirre, et al.
Transplantation and Cellular Therapy|July 28, 2024
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMORebeca Bailén, Gloria Iacoboni, Javier Delgado, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2022
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatmentsAlfonso Cortés, José L Casado, Federico Longo, et al.
Journal of Clinical Medicine|August 16, 2020
Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter StudyAlba Herrero-Morant, Carmen Álvarez-Reguera, José L Martín-Varillas, et al.
Pageof 90